You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Immunotherapeutic approaches to ovarian cancer treatment
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, March 2015
|
| DOI | 10.1186/s40425-015-0051-7 |
| Pubmed ID | |
| Authors |
Cariad Chester, Oliver Dorigo, Jonathan S Berek, Holbrook Kohrt |
| Abstract |
Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for ovarian cancer patients are inadequate. Immunotherapy offers a novel and promising therapeutic strategy for treating ovarian tumors. Following the demonstration of the immunogenicity of ovarian tumors, multiple immunotherapeutic modalities have been developed. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor-modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 135 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Malaysia | 1 | <1% |
| France | 1 | <1% |
| Sweden | 1 | <1% |
| India | 1 | <1% |
| Iran, Islamic Republic of | 1 | <1% |
| Denmark | 1 | <1% |
| Korea, Republic of | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 127 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 29 | 21% |
| Student > Master | 22 | 16% |
| Student > Bachelor | 17 | 13% |
| Student > Ph. D. Student | 11 | 8% |
| Student > Postgraduate | 11 | 8% |
| Other | 17 | 13% |
| Unknown | 28 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 22% |
| Agricultural and Biological Sciences | 29 | 21% |
| Biochemistry, Genetics and Molecular Biology | 17 | 13% |
| Immunology and Microbiology | 12 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
| Other | 13 | 10% |
| Unknown | 29 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 June 2015.
All research outputs
#15,169,543
of 25,374,647 outputs
Outputs from Journal for Immunotherapy of Cancer
#2,505
of 3,421 outputs
Outputs of similar age
#139,706
of 278,395 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#10
of 12 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,421 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 278,395 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.